retatrutide for diabetes Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide Europe - RUO Research

Gastrointestinal (GI) Sensitivity Both GLP-1 medications and moringa can affect the digestive system

According to Drucker the findings, published in December 2023, provided the first demonstration of 'a GLP-1-brain-immune axis that controls inflammation across the body independent of weight loss, even in peripheral organs devoid of GLP1 receptors.' Drucker's team has not yet identified which particular brain cells interact with GLP-1 (AAAS)

Receptor binding and functional EC characterization in HEK293 cells expressing each of the three target receptors, including human and mouse orthologs

Both groups were following diet and exercise guidance throughout, so its hard to separate the supplements effect from the lifestyle changesand with only 30 people per group, the findings are promising but far from definitive